Norris Medicines Ltd. (BSE: 524414) is an Ankleshwar, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹14 Cr, it ranks #4,611 by market cap among the 6,197 Indian listed companies on FinBizNet, and #24 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹14.16 (as of 16 Nov 2026), the share price is 29.4% below its 52-week high of ₹20.06 and 18.0% above its 52-week low of ₹12.00. The share price is down 8.1% over one year and down 13.2% over three months.
| Current Price | ₹14.16 |
|---|---|
| Market Cap | ₹14 Cr |
| BSE Code | 524414 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | 1.87% |
| Return on Assets | 0.88% |
| 52-Week Range | ₹12.00 – ₹20.06 |
| 1-Year Price Change | -8.1% |
| 3-Month Price Change | -13.2% |
| Beta (1Y) | 0.23 |
| Headquarters | Ankleshwar, Gujarat |
| Website | www.norrispharma.com |
Delivery averaged 94.8% of traded volume across 14 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Norris Medicines Limited manufactures and sells pharmaceutical formulations in India. The company offers nonsterile dosage products, such as tablets, capsules, liquid orals, and copical ointments, as well as injections and medicinal formulations. Its products include antibiotics, anti-inflammatory/pain management, antiemetic, nutrition, gastro, cough/cold, skin and allergy, antimalarial, diabetic, cardiac, dental, and other medicine products. The company also provides contract and loan license manufacturing services for pharma companies. It exports its products. Norris Medicines Limited was incorporated in 1990 and is based in Ankleshwar, India.
1. Pharmaceuticals-This segment engages in the contract manufacturing and loan license manufacturing for various multinational and Indian pharma companies.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Norris Medicines Ltd. | ₹14 Cr | n/m | 1.87% | — | -8.1% |
Listed by market capitalisation. Ratios are shown for context only.
Norris Medicines Ltd. is trading at ₹14.16, with a market capitalisation of ₹14 Cr.
Norris Medicines Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Norris Medicines Ltd. has a return on equity of 1.87%.
Norris Medicines Ltd. is listed on the BSE under the scrip code 524414.
Norris Medicines Ltd.'s share price is down 8.1% over one year and down 13.2% over three months. Its 52-week range is ₹12.00 to ₹20.06.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.